EMERGENT BIOSOLUTIONS INC. Gain (Loss) on Disposition of Assets
EMERGENT BIOSOLUTIONS INC. (EBS) reported Gain (Loss) on Disposition of Assets of -$2.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for the quarter ending 2026-06-30 was -$1.20M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for the quarter ending 2026-03-31 was -$800.00K.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for the quarter ending 2025-12-31 was -$1.00M, a 600.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for the quarter ending 2025-09-30 was -$2.20M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for fiscal 2025 was -$4.50M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for fiscal 2024 was -$28.70M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for fiscal 2023 was -$21.10M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of assets for fiscal 2022 was -$3.60M.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.00M 10-Q · filed 2026-08-06 | -$3.00M derived: sum of 3 quarters · filed 2026-08-06 | -$5.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$800.00K 10-Q · filed 2026-05-01 | -$1.80M derived: sum of 2 quarters · filed 2026-05-01 | -$4.00M derived: sum of 3 quarters · filed 2026-05-01 | -$5.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$3.20M derived: sum of 2 quarters · filed 2026-02-27 | -$4.20M derived: sum of 3 quarters · filed 2026-08-06 | -$4.50M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$3.20M derived: sum of 2 quarters · filed 2026-08-06 | -$3.50M 10-Q · filed 2025-10-30 | -$3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.30M 10-Q · filed 2026-08-06 | -$1.10M derived: sum of 3 quarters · filed 2026-08-06 | -$14.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$300.00K 10-Q · filed 2026-05-01 | -$100.00K derived: sum of 2 quarters · filed 2026-05-01 | -$13.10M derived: sum of 3 quarters · filed 2026-05-01 | -$29.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$12.80M derived: sum of 2 quarters · filed 2026-02-27 | -$28.70M derived: sum of 3 quarters · filed 2026-02-27 | -$28.70M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$28.90M derived: sum of 2 quarters · filed 2025-10-30 | -$28.90M 10-Q · filed 2025-10-30 | -$36.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$15.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$15.90M 10-Q · filed 2025-08-07 | -$23.10M derived: sum of 3 quarters · filed 2026-02-27 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | -$7.20M derived: sum of 2 quarters · filed 2026-02-27 | ||
| 2023-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$21.10M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | -$13.90M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$3.60M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |